Coloplast's New CEO Just Re-Cut the Course He Promised to Stay
A 7-8% growth ambition becomes 5-7%, a 28% margin becomes a ~25% waypoint, and Competitive Bidding finally gets a number put next to it
COLO-B.CO · Earnings Call · 2026-11-03
The course, revised
In August, three months into the job, Gavin Wood was asked bluntly by Citi's Veronika Dubajova whether he was ready to throw out the Coloplast rulebook. His answer was unambiguous.
No, I think it's too early for me to comment on it. I think I'm going to stay the course and believe in the strategy that I have.
On 3 November, delivering his first full-year result as President and CEO, the course was re-cut. The Impact4 ambition to 2030 — organic growth of 7-8%, a rising margin — is now “organic growth of 5% to 7% per year, and EBIT margin in constant currencies in the mid-20s over the period and return on invested capital around 20% in 2029-'30” — Gavin Wood, President and CEO · 2026-11-03. That is not a trim. It is a different company shape, and Wood was candid that it was a choice as much as a forecast: “our ambition is, of course, to accelerate growth and improve EBIT margin over the period. However, we wanted to be prudent and reflect the current state of the external environment into our financials.” — Gavin Wood, President and CEO · 2026-11-03
The language shift is visible in the keyword record. In the August quarter the company's own momentum list was led by "good start," "commercial execution" and "industry leading profitability." Those three have simply gone. In their place at the top of the current quarter sit Competitive Bidding, reimbursement change, the Funding the Journey program and healthcare reforms. The vocabulary of aspiration has been replaced by the vocabulary of mitigation — external headwinds and a challenging external environment now do the work that "industry leading profitability" used to do.
Two consecutive margin steps down, and a third guided
FY25-26 delivered 6% organic growth and 4% EBIT growth in constant currencies, a gross margin of 67% against 68%, and an EBIT margin before special items of 26% against 28%. Free cash flow was the genuine bright spot: DKK 6.3bn, up 16%, with a 98% trailing cash conversion. But the guidance for FY26-27 is an EBIT margin of around 25% — a third consecutive year of compression — and it is worth noting what sits inside that number: raw material and freight inflation of 3-4% on a cost of goods base of DKK 9.7bn, a Portugal ramp, and pricing reform in France and Germany. Anders Lonning-Skovgaard was explicit: “In '26/'27 financial year, reforms will be implemented in France and Germany, impacting both Chronic Care and our Dressings business.” — Anders Lonning-Skovgaard, Chief Financial Officer · 2026-11-03 Management now guides neutral to negative price for the remainder of the strategic period, a meaningful change from the long-standing assumption of roughly 1% annual price erosion.
The offset is a DKK 500m resource-reallocation exercise, with about 75% landing in FY26-27 and DKK 200m of special items. Wood was careful to frame it not as cost-cutting but as funding: roughly 80% of the freed capacity is being pushed into innovation and the U.S., “this investment level is really looking beyond 2030” — Gavin Wood, President and CEO · 2026-11-03. That is honest, but it also tells you the payback is outside the planning horizon the market is asked to underwrite.
Biologics: from a washout to a baseline
The most consequential single line in the release is the downgrade of Wound & Tissue Repair to mid-single-digit growth from "around double-digit." Biologics fell 12% in Q4, and roughly 85% of U.S. biologics sales are now inpatient versus 15% outpatient. The biologics reimbursement change has been the running sore since the January 2026 fixed payment rate, and it has now been structurally absorbed rather than awaited: Wood called Q2 of the new year “more of a clearing event for biologics” — Gavin Wood, President and CEO · 2026-11-03 as the outpatient comparison annualizes. The Biologics story has moved from growth engine to a base to be defended, and the DKK 3bn Kerecis impairment in this year's DKK 3.2bn of special items is the accounting admission of that.
Competitive Bidding stops being a hypothetical
This is the quiet pivot. In November 2025, Anders said of the U.S. Competitive Bidding Program: “we believe that if there will be an impact, and that is still highly uncertain, that it will not impact us until '28 at the earliest.” — Anders Lonning-Skovgaard, CFO · 2025-11-04 That framing — distant, uncertain, probably immaterial — is gone. The program is now explicitly baked into the 2029-30 growth and margin guidance, with management conceding it cannot quantify the price cut, only that the uncertainty is why the 5-7% range has headroom. U.S. Chronic Care, the business the whole bull case now leans on at roughly double-digit growth, is precisely the business exposed. Notably, this is not a company-specific anxiety: competitive bidding has been a live market-wide medtech keyword since appearing on the global list back in the September quarter of 2025, and the wider tape has been rewarding healthcare-policy clarity — the marketed Medicare Part D redesign theme has been a global advancer over both the 90- and 30-day windows. Coloplast's version of policy is the opposite sign.
What stopped being said, and what to watch
Two silences matter. First, commercial execution — Gavin Wood's own self-declared "one metric" when he arrived in May — has dropped out of the top of the narrative, replaced by portfolio and cost architecture. Second, and more telling, the August promise of a broader strategic update has been delivered as a numeric reset rather than a strategic one: same priority list of five, softer numbers. The candid admission on capital was that the ROIC recovery is an earnings story, not a capital-efficiency one: “Our invested capital overall, you should expect that to be flattish -- so it's really the earnings improvement over the period that will drive up our ROIC.” — Anders Lonning-Skovgaard, Chief Financial Officer · 2026-11-03 That makes invested capital discipline a promise for after 2030, not before it.
Meanwhile the input-cost backdrop is not purely idiosyncratic. Management flagged that in Q4 the Middle East conflict began lifting raw materials by more than 2% and freight by around double digits, with energy costs (about 2% of the total) substantially hedged and high-single-digit Hungarian wage inflation from January 2027. That is a mapped global macro theme now showing up in a Danish medtech P&L.
The verdict: Coloplast has stopped promising acceleration and started pricing the obstacles. The bar is now low, the Funding the Journey cash is real, free cash flow is genuinely improving, and the U.S. Chronic Care franchise plus Titan Prime give Wood something to compound. But a CEO who arrived saying he would stay the course has, in six months, widened the range, lowered the ceiling and named the 2028 risk out loud. Investors should treat the reset as credible precisely because it is unflattering — and then watch whether the "mid-20s" margin is a floor or a corridor.